微小残留病和血清游离轻链比值在多发性骨髓瘤管理中的作用
The role of minimal residual disease and serum free light chain ratio in the management of multiple myeloma.
作者信息
Zhu Long-Ying, Hu Qi-Lei, Zhang Liang, Li Zuo-Jie
机构信息
School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, 310053, Zhejiang, People's Republic of China.
Department of Clinical Laboratory, First People's Hospital of Linping District, Hangzhou, 311100, Zhejiang, People's Republic of China.
出版信息
Discov Oncol. 2024 Jun 15;15(1):229. doi: 10.1007/s12672-024-01090-1.
Multiple myeloma (MM) denotes a cancerous growth characterized by abnormal proliferation of plasma cells. Growing evidence suggests that the complexity in addressing MM lies in the presence of minimal residual disease (MRD) within the body. MRD assessment is becoming increasingly important for risk assessment in patients with MM. Similarly, the levels of serum free protein light chain and their ratio play a crucial role in assessing the disease burden and changes in MM. In this paper, we review and explore the utilization of MRD and serum free light chain ratio in the treatment of MM, delving into their respective characteristics, advantages, disadvantages, and their interrelation.
多发性骨髓瘤（MM）是一种以浆细胞异常增殖为特征的癌性生长。越来越多的证据表明，应对MM的复杂性在于体内存在微小残留病（MRD）。MRD评估对MM患者的风险评估变得越来越重要。同样，血清游离轻链水平及其比值在评估MM的疾病负担和变化中起着关键作用。在本文中，我们回顾并探讨了MRD和血清游离轻链比值在MM治疗中的应用，深入研究它们各自的特点、优点、缺点及其相互关系。
Zotero 插件